Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne muscular dystrophy amenable to exon 45 or 53 skipping.
San Antonio, Texas, September 27, 2016 – CureDuchenne, a national non-profit, and local families have joined to raise funds for research and new treatments for children afflicted with Duchenne muscular […]
Guest blog by Tammy and Scott Henegar Our family’s journey with Duchenne muscular dystrophy started in March 2011 when our 4 ½ year old adventurous and sweet young boy […]
My husband Paul and I have dreamed of this day since our son Hawken was diagnosed with Duchenne almost 15 years ago! We are overwhelmed with joy to announce […]
Eteplirsen, Developed by Sarepta, Was Made Possible in Part by Early Funding from CureDuchenne NEWPORT BEACH, California, September 19, 2016 – CureDuchenne applauds the first-ever approval of a drug in […]
Every Duchenne parent wants to know that their child is in good hands with their medical team. Physical therapy is an important part of that medical team, and Texas […]
Guest blog by Maribel and Ramiro Munoz Our son Joshua was born in 2007. Joshua, our oldest son, is an amazing and fun-loving boy. He was diagnosed with Duchenne Muscular […]
